Prolactin Receptor Antagonism in Breast Cancer
Author Information
Author(s): Sacha J Howell, Elizabeth Anderson, Tom Hunter, Gillian Farnie, Robert B Clarke
Primary Institution: Paterson Institute for Cancer Research, University of Manchester
Hypothesis
Does the prolactin receptor antagonist Δ1–9 reduce the clonogenic capacity of breast cancer cells and enhance the effectiveness of chemotherapy?
Conclusion
The prolactin receptor antagonist Δ1–9 significantly inhibits the colony-forming ability of breast cancer cells and enhances the cytotoxic effects of doxorubicin and paclitaxel.
Supporting Evidence
- Δ1–9 alone inhibited the clonogenicity in soft agar of cell lines by ~90%.
- Doxorubicin treatment increased prolactin mRNA expression in all five breast cancer cell lines tested.
- The median reduction in mammosphere forming efficiency was 56% with Δ1–9.
Takeaway
A special treatment can help stop some breast cancer cells from growing and make chemotherapy work better.
Methodology
The study used cell culture assays to assess the effects of the prolactin receptor antagonist Δ1–9 on breast cancer cell lines and primary ductal carcinoma in situ samples.
Limitations
The study primarily focused on in vitro models, which may not fully replicate in vivo conditions.
Participant Demographics
Breast cancer cell lines and primary ductal carcinoma in situ samples were used.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website